Published online before print September 30, 2002, doi: 10.1161/01.CIR.0000033973.06059.04
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2379.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
Oral Everolimus Inhibits In-Stent Neointimal Growth
From the Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC, and Cardiovascular Research and Development, Novartis Pharmaceuticals Corporation (M.F.P.), East Hanover, NJ.
Correspondence to Renu Virmani, MD, Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000. E-mail Virmani{at}afip.osd.mil
Background— Rapamycin (sirolimus)-eluting stents are associated with reduced restenosis rates in animal studies and initial human trials. The present study evaluated whether orally administered everolimus (a macrolide of the same family as sirolimus) inhibits in-stent neointimal growth in rabbit iliac arteries.
Methods and Results— New Zealand white rabbits were randomized to everolimus 1.5 mg/kg per day starting 3 days before stenting and reduced to 1 mg/kg per day from days 14 to 28 (group 1), everolimus 1.5 mg/kg given 1 day before stenting followed by 0.75 mg/kg per day for 28 days (group 2), or matching placebo for each group. Drugs were administered by oral gavage. Stents were deployed in both iliac arteries, and arteries were harvested 28 days after stenting. Group 1 everolimus-treated rabbits experienced weight loss and anorexia, which resolved after the everolimus dose was lowered on day 14. Group 2 animals were healthy for the duration of everolimus dosing. Both everolimus treatment groups significantly reduced in-stent neointimal growth (46% reduction and 42% reduction in intimal thickness in groups 1 and 2, respectively). In group 2 everolimus-treated animals, the neointima was healed or healing, characterized by stent struts covered by a thin neointima, overlying endothelial cells, and only small foci of fibrin. Scanning electron microscopy showed >80% stent surface endothelialization in group 2 everolimus-treated rabbits.
Conclusions— Oral everolimus suppresses in-stent neointimal growth in the rabbit iliac artery. At a dose of 1.5 mg/kg given 1 day before stenting followed by 0.75 mg/kg per day for 28 days, everolimus was well tolerated and was associated with significant neointimal healing.
Key Words: pathology • restenosis • stent
Related Article:
Circulation 2002 106: 2296-2298.
This article has been cited by other articles:
 |
|
 |
|
  B. E. Stahli, G. G. Camici, and F. C. Tanner Drug-eluting stent thrombosis Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 45 - 52. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Baetta, A. Granata, M. Canavesi, N. Ferri, L. Arnaboldi, S. Bellosta, P. Pfister, and A. Corsini Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferri, A. Granata, C. Pirola, F. Torti, P. J. Pfister, R. Dorent, and A. Corsini Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27Kip1/Cyclin E Expression Mol. Pharmacol., July 1, 2008; 74(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cheng, D. Tempel, A. Oostlander, F. Helderman, F. Gijsen, J. Wentzel, R. van Haperen, D. B. Haitsma, P. W. Serruys, A. F.W. van der Steen, et al. Rapamycin modulates the eNOS vs. shear stress relationship Cardiovasc Res, April 1, 2008; 78(1): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Nuhrenberg, N. Langwieser, J. B.K. Schwarz, Y. Hou, P. Frank, F. Sorge, S. Matschurat, S. Seidl, A. Kastrati, A. Schomig, et al. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury Cardiovasc Res, February 1, 2008; 77(3): 580 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ribichini, M. Joner, V. Ferrero, A. V. Finn, J. Crimins, G. Nakazawa, E. Acampado, F. D. Kolodgie, C. Vassanelli, and R. Virmani Effects of Oral Prednisone After Stenting in a Rabbit Model of Established Atherosclerosis J. Am. Coll. Cardiol., July 10, 2007; 50(2): 176 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Finn, G. Nakazawa, M. Joner, F. D. Kolodgie, E. K. Mont, H. K. Gold, and R. Virmani Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1500 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ilkay, L. Tirikli, I. Ozercan, M. Yavuzkir, I. Karaca, A. Rahman, and N. Arslan Oral Mycophenolate Mofetil Prevents In-Stent Intimal Hyperplasia Without Edge Effect Angiology, October 1, 2006; 57(5): 577 - 584. [Abstract] [PDF]
|
|
|
|
|
|
A. E. Rodriguez, J. F. Granada, M. Rodriguez-Alemparte, C. F. Vigo, J. Delgado, C. Fernandez-Pereira, A. Pocovi, A. M. Rodriguez-Granillo, D. Schulz, A. E. Raizner, et al. Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1522 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A E Rodriguez, M Rodriguez Alemparte, C F Vigo, C Fernandez Pereira, C Llaurado, D Vetcher, A Pocovi, and J Ambrose Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial) Heart, November 1, 2005; 91(11): 1433 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fukuda, M. Sata, K. Tanaka, and R. Nagai Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells Circulation, February 22, 2005; 111(7): 926 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, A. E. Ajani, A. D. Pichard, R. Torguson, E. Pinnow, D. Canos, L. F. Satler, K. M. Kent, P. Kuchulakanti, C. Pappas, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Bestehorn, F.-J. Neumann, H. J. Buttner, P. Betz, P. Sturzenhofecker, E. von Hodenberg, A. Verdun, L. Levai, J. P. Monassier, and H. Roskamm Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2160 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-W. Kim, J.-S. Kwon, Y.-G. Kim, M. S. Kim, G.-S. Lee, T.-J. Youn, and M.-C. Cho Novel Oral Formulation of Paclitaxel Inhibits Neointimal Hyperplasia in a Rat Carotid Artery Injury Model Circulation, March 30, 2004; 109(12): 1558 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Mourani, P. J. Garl, J. M. Wenzlau, T. C. Carpenter, K. R. Stenmark, and M. C.M. Weiser-Evans Unique, Highly Proliferative Growth Phenotype Expressed by Embryonic and Neointimal Smooth Muscle Cells Is Driven by Constitutive Akt, mTOR, and p70S6K Signaling and Is Actively Repressed by PTEN Circulation, March 16, 2004; 109(10): 1299 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsumoto, T. Uwatoku, K. Oi, K. Abe, T. Hattori, K. Morishige, Y. Eto, Y. Fukumoto, K.-i. Nakamura, Y. Shibata, et al. Long-Term Inhibition of Rho-Kinase Suppresses Neointimal Formation After Stent Implantation in Porcine Coronary Arteries: Involvement of Multiple Mechanisms Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, P. W. Serruys, and M. A. Costa New Frontiers in Cardiology: Drug-Eluting Stents: Part I Circulation, May 6, 2003; 107(17): 2274 - 2279. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Faxon Systemic Drug Therapy for Restenosis: "Deja Vu All Over Again" Circulation, October 29, 2002; 106(18): 2296 - 2298. [Full Text] [PDF]
|
|